Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
Globe Newswire3-09-2024, 19:00
Carr, Riggs & Ingram Chooses Caseware and the Dynamic Audit Solution (DAS) Suite to Power its Audit Future for the Agentic Age 21-04-2026, 19:50